The analysis included four randomized controlled trials and 19 non-randomized studies, primarily involving cannabidiol, a particular type of cannabinoid that does not have psychoactive effects.
Among randomized controlled trials involving children with severe forms of epilepsy, there was no statistically significant difference between cannabidiol and placebo in terms of freedom from seizures, sleep disruption, or vomiting. There was a statistically significant reduction in the median frequency of monthly seizures with cannabidiol compared with placebo and an increase in number of participants with at least a 50 percent reduction in seizures.
“Although we saw no significant difference in the number of children who
...read more at https://www.sciencedaily.com/releases/2018/12/181205093644.htm